¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"test type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • occult blood test
    ÀáÇ÷°Ë»ç
  • one-tail test
    ´ÜÃø°ËÁ¤
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´ç³»¼º°Ë»ç
  • osmotic fragility test
    »ïÅõ¾ÐÃë¾à¼º°Ë»ç
  • oxytocin challenge test
    ¿Á½ÃÅä½ÅºÎÇϰ˻ç
  • pin-prick test
    ¹Ù´Ãµû²û°Ë»ç, ħÅë°¢°Ë»ç
  • positioning nystagmus test
    À§Ä¡´«¶³¸²°Ë»ç, µÎÀ§º¯È¯¾ÈÁø°Ë»ç
  • Pap test
    ÆÄÆÄ´ÏÄݷΰ˻ç, ÀڱðæºÎÁú¼¼Æ÷Áø°Ë»ç
  • Papanicolaou test
    ÆÄÆÄ´ÏÄݷΰ˻ç, ÀڱðæºÎÁú¼¼Æ÷Áø°Ë»ç
  • postcoital test
    ¼º±³Èİ˻ç
  • precipitin test
    ħÀü¼Ò°Ë»ç(¹ý)
  • pregnancy test
    ÀӽŰ˻ç
  • projective test
    Åõ»ç°Ë»ç
  • protection test
    ÁßÈ­°Ë»ç, ¹æ¾î°Ë»ç
  • pulmonary function test
    Æó±â´É°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • exercise tolerance test
    ¿îµ¿³»¼º°Ë»ç
  • eye tracking test
    ½ÃÇ¥ÃßÀû°Ë»ç, ½ÃÇ¥ÃßÀû°Ë»ç
  • fermentation test
    ¹ßÈ¿½ÃÇè
  • fern test
    ¾çÄ¡Çü¼º°Ë»ç
  • fibrinogen consumption test
    ¼¶À¯¼Ò¿ø¼Òºñ°Ë»ç
  • field test
    ½ÇÁõ°Ë»ç
  • finger-nose test
    ¼Õ°¡¶ôÄÚ°Ë»ç
  • finger-to-finger test
    ¼Õ°¡¶ô¸Â´ë±â°Ë»ç
  • fistula test
    »û±æ°Ë»ç, ´©°ø°Ë»ç
  • flocculation test
    ¼ØÅÐħÀü°Ë»ç
  • fluctuation test
    µé³¯Âߺ¯À̰˻ç
  • fluorescent antibody test
    Çü±¤Ç×ü°Ë»ç
  • fluorescent treponemal antibody test
    Çü±¤¸Åµ¶Ç×ü°Ë»ç
  • forced duction test
    °­Á¦´ç±è°Ë»ç
  • forward traction test
    ¾ÕÂÊ´ç±è°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • Mantouxs test
    ¸Á¶Ñ ÇǺιÝÀÀ°Ë»ç
  • Meinickes test
    ¸¶ÀÌ´ÏÄÉ ¸Åµ¶°Ë»ç¹ý
  • Moloneys test
    ¸ô·Î´Ï µðÇÁÅ׸®¾Æµ¶¼Ò½ÃÇè
  • Montenegro test
    ¸óÅ׳ױ׷Π°Ë»ç
  • Multistix test
    ¸ÖƼ½ºÆ½½º½ÃÇè
  • PB score [=phonetic balance test]
    ¸í·áµµÄ¡
  • PIAT.see Peabody Individual Achievement Test
    Çǹٵ𠰳ÀμºÃëµµ °Ë»ç
  • PPD(Purified protein derivative) test
    PPD °Ë»ç.
  • Paigen test
    ÆÄÀ̰սÃÇè
  • Paul-Bunnell test
    Æú-¹ø³Ú °Ë»ç¹ý
  • Paul-Bunnell-Davidsohn test
    Æú-¹ö³Ú-´Ùºñµå¼Õ ½ÃÇè
  • Perls iron test
    Æä¸¦Áîö½ÃÇè
  • Phenstix test
    Ææ½ºÆ½½º°Ë»ç
  • Prausnitz-Kustner test
    ÇÁ¶ó¿ì´ÏÃ÷-Äû½ºÆ®³Ê½ÃÇè.
  • Prausnitz-Kustner test
    ÇÁ¶ó¿ì½º´ÏÃ÷ Äû½ºÆ®³Ê °Ë»ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • spinal type
    ô¼öÇü(ô±âÐúþ).
  • split electrode type probe
    ºÐÇÒ Àü±Ø ŽÃËÀÚ
  • split-electrode-type probe
    ºÐÇÒ Àü±Ø ŽÃËÀÚ (ÝÂùÜ ï³Ð¿ ÷®õºí­)
  • sthenic type
    ±Ù·ÂÇü(ÐÉæ³úþ).
  • storage-type
    ÃàÀûÇü
  • supporting cell [type ii glomus cell]
    ¹öÆÀ¼¼Æ÷
  • swaged cast type crown
    ¾ÐÀÎÇü±Ý°ü(äâìÔû¡ ÐÝή).
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü(¡­ÑÌíåúþ).
  • sympathicotonic type
    ±³°¨½Å°æ±äÀåÇü(¡­ÑÌíåúþ)
  • thinking type
    »ç°íÇü(ÞÖÍÅúþ).
  • triaxone type
    »ïÃàÇü(ß²õîúþ).
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆÑÛ).
  • tuberculoid (type) leprosy
    À¯°áÇÙ³ª(׾̿ú·ÑÛ), °áÇپ糪(Ì¿ú·åÆ )
  • type A behavior
    AÇü Çൿ(ú¼ÔÑ).
  • type A encephalitis
    ±â¸é¼º ³ú¿°(ÐîØùàõÒàæú).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
PFT   1) Platelet Function Test
  2) Pulmonary Function Test
PK test Prausnitz-Ku:stner test
PSP test Phenol-Sulfon-Phthalein test
RAST Radio-Allergo-Sorbent Test
  ; Specific IgE Test
RNS test Repetitive Nerve Stimulation test
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
FOBT Faecal occult blood test
FTND Fagerstrom Test for Nicotine Dependence
FUT Fibrinogen Uptake Test
FAT Fluorescent Antibody Test
FTA-ABS Fluorescent Treponema Antibody-Absorption test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • chromium-51 release test
    Å©·Î¹Å-51 ¹æÃâ ½ÇÇè
    »ì¾ÆÀÖ´Â ¼¼Æ÷¿¡
  • citrate test
    ±¸¿¬»ê¿° ½ÃÇè
  • clomiphene test
    Ŭ·Î¹ÌÆæ ½ÃÇè
  • clonidine test
    Ŭ·Î´Ïµò ½ÃÇè
  • closed cup flash test
    ¹ÐÆó½Ä ÀÎÈ­Á¡ ½ÃÇè
  • coagulase test
    ÄھƱֶóÁ¦ ½ÃÇè
  • coccidioidin test
    Ä۽õð¿ÀÀ̵ò ½ÃÇè
  • coin test
    µ¿Àü ½ÃÇè
  • cold caloric test
    ÇÑ·© ¿­ ½ÃÇè
  • cold pressor test
    ÇÑ·© Ç÷¾Ð ¹ÝÀÀ °Ë»ç
  • cold water test
    ħ¼ö¹ý
  • collateral circulation test
    ÃøºÎ ¼øÈ¯ ½ÃÇè
  • colloidal gold test
    ±³»ó±Ý °Ë»ç, ±³»ó ¿°È­±Ý ½ÃÇè
  • color blindness test chart
    »ö°¢ °Ë»çÇ¥, »ö¸Í °Ë»çÇ¥
  • color form sorting test
    »öä ÇüÅ Ã߸®±â °Ë»ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
type II hyperlipoproteinaemia <biochemistry> A relatively rare (7 out of 1,000) genetic disease in which there is elevation in the blood triglycerides, cholesterol and low density lipoprotein (LDL). Also called type II hyperlipoproteinaemia, familial hyperlipoproteinaemia or familial hypercholesterolaemia.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III acrocephalosyndactyly An autosomal dominant syndrome with variable expression of brachycephaly, maxillary hypoplasia, prominent ear crus, syndactyly, facial asymmetry, shallow orbits, telecanthus, and nasal septal deviation; may show mental retardation.
Synonym: Saethre-Chotzen syndrome.
(05 Mar 2000)
type III collagen Collagen characteristic of reticular fibres.
(05 Mar 2000)
type III familial hyperlipoproteinaemia Hyperlipoproteinaemia characterised by increased plasma levels of LDL, beta-lipoproteins, pre-beta-lipoproteins, cholesterol, phospholipids, and triglycerides; hypertriglyceridemia induced by a high carbohydrate diet, and glucose tolerance is abnormal; frequent eruptive xanthomas and atheromatosis, particularly coronary artery disease; biochemical defect lies in apolipoproteins; there are many varieties.
Synonym: carbohydrate-induced hyperlipaemia, dysbetalipoproteinaemia, familial hyperbetalipoproteinaemia and hyperprebetalipoproteinaemia, familial hypercholesterolaemia with hyperlipaemia.
(05 Mar 2000)
type III hyperlipoproteinaemia <biochemistry> An inherited disorder (gene defect) where both cholesterol and triglycerides are elevated in the same patient. This condition accelerates the effects of atherosclerosis and thus increases the risk of cardiovascular disease. Conditions such as hypothyroidism, obesity and diabetes enhances this risk.
Origin: Gr. Haima = blood
(27 Sep 1997)
type III hypersensitivity reaction An immunologic category of diseases evoked by the deposition of antigen-antibody or antigen-antibody-complement complexes on cell surfaces, with subsequent involvement of breakdown products of complement, platelets, and polymorphonuclear leukocytes, and development of vasculitis; nephritis is common. Arthus phenomenon and serum sickness are classic examples, but many other disorders, including most of the connective tissue disease's, may belong in this immunologic category; immune complex disease's can also occur during a variety of disease's of known aetiology, such as subacute bacterial endocarditis.
See: autoimmune disease.
Synonym: immune complex disorder, type III hypersensitivity reaction.
(05 Mar 2000)
type III mucopolysaccharidosis <syndrome> An error of the mucopolysaccharide metabolism, with excretion of large amounts of heparan sulfate in the urine and severe mental retardation with hepatomegaly; skeleton may be normal or may present mild changes similar to those in Hurler's syndrome; several different types (A, B, C, and D) have been identified according to the enzyme deficiency; autosomal recessive inheritance.
Synonym: type III mucopolysaccharidosis.
(05 Mar 2000)
type II interferon <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
type II mortality <epidemiology> A mortality schedule in which all hosts are assumed to die at a constant rate. This constant rate is equal to the inverse of the life expectancy.
(05 Dec 1998)
type II mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism characterised by deficiency of iduronate sulfatase, with excretion of dermatan sulfate and heparan sulfate in the urine; clinically similar to Hurler's syndrome but distinguished by less severe skeletal changes, no corneal clouding, and X-linked recessive inheritance.
Synonym: type II mucopolysaccharidosis.
(05 Mar 2000)
type I interferon <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
type I mortality <epidemiology> A mortality schedule in which all hosts are assumed to live for a fixed number of years equal to the life expectancy.
(05 Dec 1998)
type IS mucopolysaccharidosis <syndrome> A hereditary metabolic disorder caused by a recessive gene which results in a deficiency of the enzyme alpha-L-iduronidase, which breaks down dermatan sulphate and heparan sulphate, two types of mucopolysaccharides (complex carbohydrates). Consequently, the mucopolysaccharides accumulate in the cells of the body and cause damage.
Symptoms include skeletal deformities, mental retardation, coronary artery disease, deafness, and stiff joints, among other things. There are mild and severe forms of the syndrome, the severe form is called Hurler syndrome, the mild form is called Scheie Syndrome, and children with an intermediate form have Hurler-Scheie Syndrome. Patients with the mild form generally suffer little to no mental retardation and survive to adulthood. There is presently no cure. Scheie's Syndrome is one of a number of related rare genetic mucopolysaccharide disorders, the most common being Hunter syndrome.
(09 Oct 1997)
type IVA,B mucopolysaccharidosis <syndrome> An error of mucopolysaccharide metabolism with excretion of keratan sulfate in urine; characterised by severe skeletal defects with short stature, severe deformity of spine and thorax, long bones with irregular epiphyses but with shafts of normal length, enlarged joints, flaccid ligaments, and waddling gait; autosomal recessive inheritance; type IV A mucopolysaccharidosis is due to an absence of galactose-1-sulfatase, while type IV B is due to a deficiency of a beta-galactosidase.
Synonym: Brailsford-Morquio disease, Morquio's disease, Morquio-Ullrich disease, type IVA, B mucopolysaccharidosis.
(05 Mar 2000)
type IV acrocephalosyndactyly Acrocephalosyndactyly with pointed nose, hypertelorism, cleft palate, congenital heart disease and pseudohermaphroditism; contractures of elbows and knees; soft tissue syndactyly, absent first metatarsal and great toe. Autosomal recessive.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á